Limited published information exists regarding tacrolimus dosing when transitioning from voriconazole to itraconazole
66, p = 0
Patients transplanted from 2007 were included in the 2007-006416-32 GEL-TAMO/GETH trial and received GVHD prophylaxis consisting of sirolimus at a dose of 6 mg/day p
02 mg/kg/day as a continuous i
However, studies in HCT recipients are needed because these patients are typically using concomitant
Antifungal
Antifungal prophylaxis is routinely administered to lung transplant recipients, but the best approach, optimal duration, and cost-effectiveness of different antifungal prophylaxis strategies are unknown
Certain antifungal agents require therapeutic drug monitoring (see section 6
Antifungal prophylaxis is not recommended to prevent coccidioidomycosis in patients infected with HIV living in coccidioidal-endemic regions No clinical studies exist to guide the optimal dose or duration of fluconazole or other antifungal therapy for persons with primary pulmonary coccidioidomycosis
Prophylactic antifungal agents in this setting must be potent and be able to rapidly achieve the systemic drug levels considered adequate for activity and this duration of prophylaxis spans the period of greatest vulnerability to It should be noted that itraconazole will increase cyclo-sporine or tacrolimus levels by 35% We compared effectiveness and tolerability of isavuconazole and voriconazole prophylaxis in lung transplant recipients